New Frontiers in the Therapy of Primary Immunodeficiency: From Gene Addition to Gene Editing

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2017 Mar 9

PMID 28270364

Citations 21

Authors

Donald B Kohn

Caroline Y Kuo

Affiliations

Soon will be listed here.

Abstract

The most severe primary immune deficiency diseases (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for more than 4 decades. However, such transplantations have the best outcomes when there is a well-matched donor available because immune complications, such as graft-versus-host disease, are greater without a matched sibling donor. Gene therapy has been developed as a method to perform autologous transplantations of a patient's own stem cells that are genetically corrected. Through an iterative bench-to-bedside-and-back process, methods to efficiently add new copies of the relevant gene to hematopoietic stem cells have led to safe and effective treatments for several PIDs, including forms of severe combined immune deficiency, Wiskott-Aldrich syndrome, and chronic granulomatous disease. New methods for gene editing might allow additional PIDs to be treated by gene therapy because they will allow the endogenous gene to be repaired and expressed under its native regulatory elements, which are essential for genes involved in cell processes of signaling, activation, and proliferation. Gene therapy is providing exciting new treatment options for patients with PIDs, and advances are sure to continue.

Citing Articles

Antiviral options and therapeutics against influenza: history, latest developments and future prospects.

Meseko C, Sanicas M, Asha K, Sulaiman L, Kumar B Front Cell Infect Microbiol. 2023; 13:1269344.

PMID: 38094741 PMC: 10716471. DOI: 10.3389/fcimb.2023.1269344.

Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.

Labrosse R, Chu J, Armant M, Everett J, Pellin D, Kareddy N Blood. 2023; 142(15):1281-1296.

PMID: 37478401 PMC: 10731922. DOI: 10.1182/blood.2022019117.

Advances in CRISPR/Cas gene therapy for inborn errors of immunity.

Liu X, Li G, Liu Y, Zhou F, Huang X, Li K Front Immunol. 2023; 14:1111777.

PMID: 37051232 PMC: 10083256. DOI: 10.3389/fimmu.2023.1111777.

CRISPR/Cas systems usher in a new era of disease treatment and diagnosis.

Li R, Wang Q, She K, Lu F, Yang Y Mol Biomed. 2022; 3(1):31.

PMID: 36239875 PMC: 9560888. DOI: 10.1186/s43556-022-00095-y.

Gene Edited T Cell Therapies for Inborn Errors of Immunity.

Fox T, Houghton B, Booth C Front Genome Ed. 2022; 4:899294.

PMID: 35783679 PMC: 9244397. DOI: 10.3389/fgeed.2022.899294.

References

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

Fischer A, Hacein-Bey Abina S, Thrasher A, von Kalle C, Cavazzana-Calvo M . LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med. 2004; 350(24):2526-7. DOI: 10.1056/NEJM200406103502422. View

Gaspar H, Cooray S, Gilmour K, Parsley K, Adams S, Howe S . Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2011; 3(97):97ra79. DOI: 10.1126/scitranslmed.3002715. View

Dick J, Magli M, Huszar D, Phillips R, Bernstein A . Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell. 1985; 42(1):71-9. DOI: 10.1016/s0092-8674(85)80102-1. View

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman M . Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17(11):1919-28. PMC: 2835038. DOI: 10.1038/mt.2009.179. View

Czechowicz A, Kraft D, Weissman I, Bhattacharya D . Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007; 318(5854):1296-9. PMC: 2527021. DOI: 10.1126/science.1149726. View

de Ravin S, Wu X, Moir S, Anaya-OBrien S, Kwatemaa N, Littel P . Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016; 8(335):335ra57. PMC: 5557273. DOI: 10.1126/scitranslmed.aad8856. View

Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A . Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007; 117(8):2233-40. PMC: 1934603. DOI: 10.1172/JCI31666. View

10.

Carbonaro D, Zhang L, Jin X, Montiel-Equihua C, Geiger S, Carmo M . Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. 2013; 22(3):607-622. PMC: 3944341. DOI: 10.1038/mt.2013.265. View

11.

Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S . Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther. 2009; 17(6):1073-82. PMC: 2835187. DOI: 10.1038/mt.2009.31. View

12.

Naldini L, Trono D, Verma I . Lentiviral vectors, two decades later. Science. 2016; 353(6304):1101-2. DOI: 10.1126/science.aah6192. View

13.

Joglekar A, Hollis R, Kuftinec G, Senadheera S, Chan R, Kohn D . Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther. 2013; 21(9):1705-17. PMC: 3776625. DOI: 10.1038/mt.2013.106. View

14.

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

15.

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A . Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296(5577):2410-3. DOI: 10.1126/science.1070104. View

16.

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View

17.

Kang E, Choi U, Theobald N, Linton G, Long Priel D, Kuhns D . Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2009; 115(4):783-91. PMC: 2815517. DOI: 10.1182/blood-2009-05-222760. View

18.

Gaspar H, Cooray S, Gilmour K, Parsley K, Zhang F, Adams S . Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011; 3(97):97ra80. DOI: 10.1126/scitranslmed.3002716. View

19.

Chhabra A, Ring A, Weiskopf K, Schnorr P, Gordon S, Le A . Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med. 2016; 8(351):351ra105. PMC: 6668627. DOI: 10.1126/scitranslmed.aae0501. View

20.

Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell M . Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther. 2010; 19(1):122-32. PMC: 3017453. DOI: 10.1038/mt.2010.226. View